On the public citation graph
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
0 signed · 228 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamanetworkopen.2020.1997openalex-snapshot
Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults
inferredcites →https://doi.org/10.1002/hep.28785openalex-snapshot
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
inferredcites →https://doi.org/10.1002/hep.30254openalex-snapshot
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
inferredcites →https://doi.org/10.1002/hep.31420openalex-snapshot
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
inferredcites →https://doi.org/10.1002/hep4.1387openalex-snapshot
Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1002/hep4.1710openalex-snapshot
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1002/hep4.1765openalex-snapshot
Poor Awareness of Liver Disease Among Adults With NAFLD in the United States
inferredcites →https://doi.org/10.1016/j.cgh.2014.04.014openalex-snapshot
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
inferredcites →https://doi.org/10.1016/j.cgh.2015.08.010openalex-snapshot
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
inferredcites →https://doi.org/10.1016/j.cgh.2018.04.043openalex-snapshot
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cgh.2019.01.001openalex-snapshot
Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.cgh.2020.08.017openalex-snapshot
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018
inferredcites →https://doi.org/10.1016/j.cgh.2021.06.048openalex-snapshot
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cgh.2021.07.020openalex-snapshot
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
inferredcites →https://doi.org/10.1016/j.jhep.2013.04.027openalex-snapshot
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
inferredcites →https://doi.org/10.1016/j.jhep.2014.11.034openalex-snapshot
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
inferredcites →https://doi.org/10.1016/j.jhep.2018.05.036openalex-snapshot
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
inferredcites →https://doi.org/10.1016/j.jhep.2020.03.039openalex-snapshot
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
inferredcites →https://doi.org/10.1016/j.jhep.2020.08.028openalex-snapshot
The times they are a-changin' (for NAFLD as well)
inferredcites →https://doi.org/10.1016/j.jhep.2021.07.035openalex-snapshot
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
inferredcites →https://doi.org/10.1016/j.jhepr.2021.100305openalex-snapshot
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/j.jval.2018.04.555openalex-snapshot
Global Prevalence of Nonalcoholic Steatohepatitis (NASH): Findings from a Targeted Literature Review
inferredcites →https://doi.org/10.1016/s0016-5085(99)70506-8openalex-snapshot
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
inferredcites →https://doi.org/10.1016/s0025-6196(24)00530-5openalex-snapshot
Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1038/nrgastro.2017.109openalex-snapshot
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
inferredcites →https://doi.org/10.1038/s41591-018-0104-9openalex-snapshot
Mechanisms of NAFLD development and therapeutic strategies
inferredcites →https://doi.org/10.1053/j.gastro.2004.11.018openalex-snapshot
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.005openalex-snapshot
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.043openalex-snapshot
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2018.12.036openalex-snapshot
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2019.11.312openalex-snapshot
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2020.11.051openalex-snapshot
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
inferredcites →https://doi.org/10.1097/md.0b013e3182779d49openalex-snapshot
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
inferredcites →https://doi.org/10.1111/apt.15580openalex-snapshot
The impact of modifiable risk factors on the long‐term outcomes of non‐alcoholic fatty liver disease
inferredcites →https://doi.org/10.1111/hepr.13535openalex-snapshot
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong
inferredcites →https://doi.org/10.1111/joim.13035openalex-snapshot
Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016
inferredcites →https://doi.org/10.1111/liv.13992openalex-snapshot
Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1111/liv.14675openalex-snapshot
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
inferredcites →https://doi.org/10.1136/gut.2009.205088openalex-snapshot
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
inferredcites →https://doi.org/10.1136/gutjnl-2019-318813openalex-snapshot
Epidemiology of chronic liver diseases in the USA in the past three decades
inferredcites →https://doi.org/10.1148/radiol.2015150619openalex-snapshot
Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement
inferredcites →https://doi.org/10.1186/1741-7015-9-48openalex-snapshot
Metabolic syndrome: definitions and controversies
inferredcites →https://doi.org/10.14309/ajg.0000000000000375openalex-snapshot
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
inferredcites →https://doi.org/10.2214/ajr.15.14552openalex-snapshot
Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 1, Principles and Techniques
inferredcites →https://doi.org/10.4103/sjg.sjg_122_18openalex-snapshot
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
inferredcites →https://doi.org/10.4135/9781412953948.n305openalex-snapshot
National Health and Nutrition Examination Survey
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/cld.1250openalex-snapshot
The Shift from nonalcoholic fatty liver disease to metabolic dysfunction–associated fatty liver disease
inferred← citeshttps://doi.org/10.1002/fsn3.71026openalex-snapshot
Synergistic Effects of Dietary Protein and Vitamin E Intake on Reducing Metabolic‐Associated Fatty Liver Disease Risk: Insights From NHANES [2017–2023] and Mendelian Randomization Study
inferred← citeshttps://doi.org/10.1002/hep.32552openalex-snapshot
The transition from NAFLD to MAFLD: One size still does not fit all—Time for a tailored approach?
inferred← citeshttps://doi.org/10.1002/hep.32563openalex-snapshot
Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD
inferred← citeshttps://doi.org/10.1002/hep.32564openalex-snapshot
Letter to the editor: Apples should be compared with apples
inferred← citeshttps://doi.org/10.1002/hep.32642openalex-snapshot
Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
inferred← citeshttps://doi.org/10.1002/inm3.3openalex-snapshot
Extracellular Vesicles in Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities
inferred← citeshttps://doi.org/10.1002/mco2.70087openalex-snapshot
Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study
inferred← citeshttps://doi.org/10.1007/978-3-031-33548-8_12openalex-snapshot
Nonalcoholic Fatty Liver Disease Within Other Causes of Chronic Liver Diseases
inferred← citeshttps://doi.org/10.1007/s00394-025-03809-4openalex-snapshot
Higher diet quality is associated with a lower prevalence of MASLD and adverse health outcomes: insights from NHANES 2005 to 2020
inferred← citeshttps://doi.org/10.1007/s00464-025-11785-3openalex-snapshot
Liver resection versus interventional treatments for hepatocellular carcinoma patients with hypohepatia: a multicenter study
inferred← citeshttps://doi.org/10.1007/s10238-025-01818-5openalex-snapshot
Innovative machine learning approach for liver fibrosis and disease severity evaluation in MAFLD patients using MRI fat content analysis
inferred← citeshttps://doi.org/10.1007/s10620-023-07860-1openalex-snapshot
Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease
inferred← citeshttps://doi.org/10.1007/s10620-024-08723-zopenalex-snapshot
Association of Comorbidity Duration with the Occurrence and Prognosis of Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1007/s12072-023-10512-1openalex-snapshot
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis
inferred← citeshttps://doi.org/10.1007/s12072-023-10550-9openalex-snapshot
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
inferred← citeshttps://doi.org/10.1007/s12072-023-10568-zopenalex-snapshot
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
inferred← citeshttps://doi.org/10.1007/s12072-024-10661-xopenalex-snapshot
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
inferred← citeshttps://doi.org/10.1007/s12072-024-10748-5openalex-snapshot
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study
inferred← citeshttps://doi.org/10.1016/b978-0-323-99649-5.00012-1openalex-snapshot
Noninvasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.actpsy.2025.105041openalex-snapshot
Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults
inferred← citeshttps://doi.org/10.1016/j.ajpc.2025.101049openalex-snapshot
Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100762openalex-snapshot
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100765openalex-snapshot
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100774openalex-snapshot
New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101179openalex-snapshot
From NAFLD to MASLD: Promise and pitfalls of a new definition
inferred← citeshttps://doi.org/10.1016/j.bcp.2023.115900openalex-snapshot
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.cgh.2022.06.029openalex-snapshot
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cgh.2022.09.028openalex-snapshot
The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
inferred← citeshttps://doi.org/10.1016/j.cgh.2022.10.034openalex-snapshot
Letter to the Editor: Nonalcoholic Fatty Liver Disease Without Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome
inferred← citeshttps://doi.org/10.1016/j.cld.2024.06.002openalex-snapshot
Alcohol and Metabolic Syndrome Interaction
inferred← citeshttps://doi.org/10.1016/j.clinimag.2024.110097openalex-snapshot
Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
inferred← citeshttps://doi.org/10.1016/j.clinsp.2025.100686openalex-snapshot
Construction and validation of a nomogram for detecting chronic kidney disease in patients with nonalcoholic fatty liver disease: Insights from the NHANES database
inferred← citeshttps://doi.org/10.1016/j.dld.2024.09.027openalex-snapshot
The association analysis between exposure to volatile organic compounds and fatty liver disease in US Adults
inferred← citeshttps://doi.org/10.1016/j.dld.2025.04.028openalex-snapshot
Author's reply: “Comment on “The association analysis between exposure to volatile organic compounds and fatty liver disease in US Adults””
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2023.114720openalex-snapshot
Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2023.114836openalex-snapshot
The association between endocrine disrupting chemicals and MAFLD: Evidence from NHANES survey
inferred← citeshttps://doi.org/10.1016/j.ejim.2023.01.029openalex-snapshot
Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study
inferred← citeshttps://doi.org/10.1016/j.gastha.2025.100629openalex-snapshot
Steatotic Liver Disease in the US: The Impact of the New Nomenclature on Classification of Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease
inferred← citeshttps://doi.org/10.1016/j.gastre.2025.502442openalex-snapshot
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.gastre.2026.502639openalex-snapshot
Corrigendum. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2025.502442openalex-snapshot
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2025.502639openalex-snapshot
Corrigendum. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.142275openalex-snapshot
Mechanism of liver x receptor alpha in intestine, liver and adipose tissues in metabolic associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jceh.2024.102387openalex-snapshot
Effect of Immunosuppressive Regimens on Metabolic Dysfunction-associated Fatty Liver Disease Following Liver Transplantation
inferred← citeshttps://doi.org/10.1016/j.jep.2025.121126openalex-snapshot
Puerarin from Pueraria montana var. lobata (Willd.) alleviates hepatic steatosis and inflammation in MAFLD through suppressing STING-IRF3/NF-κB signaling in macrophages
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.07.012openalex-snapshot
Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.08.003openalex-snapshot
Comparison of mortality outcomes in individuals with MASLD and/or MAFLD
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.09.030openalex-snapshot
The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.09.038openalex-snapshot
From NAFLD to MASLD: Promise and pitfalls of a new definition
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.01.014openalex-snapshot
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.05.024openalex-snapshot
Reply to: Correspondence on “clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease’
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.06.036openalex-snapshot
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.10.026openalex-snapshot
Reply to: “ “Fatty” or “steatotic”: Position statement from a linguistic perspective by the Chinese-speaking community”
inferred← citeshttps://doi.org/10.1016/j.jhepr.2023.100721openalex-snapshot
Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jhepr.2024.101172openalex-snapshot
ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population
inferred← citeshttps://doi.org/10.1016/j.metabol.2023.155642openalex-snapshot
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
inferred← citeshttps://doi.org/10.1016/j.numecd.2023.01.013openalex-snapshot
Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study
inferred← citeshttps://doi.org/10.1016/j.numecd.2024.05.018openalex-snapshot
Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups
inferred← citeshttps://doi.org/10.1016/j.numecd.2024.09.001openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.107972openalex-snapshot
The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery
inferred← citeshttps://doi.org/10.1016/j.redox.2024.103314openalex-snapshot
Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation
inferred← citeshttps://doi.org/10.1038/s41387-024-00339-6openalex-snapshot
Associations of traditional healthy lifestyle and sleep quality with metabolic dysfunction-associated fatty liver disease: two population-based studies
inferred← citeshttps://doi.org/10.1038/s41575-026-01235-3openalex-snapshot
The dynamic spectrum of steatotic liver disease: the global perspective
inferred← citeshttps://doi.org/10.1038/s41598-024-60152-0openalex-snapshot
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
inferred← citeshttps://doi.org/10.1038/s41598-024-63453-6openalex-snapshot
Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study
inferred← citeshttps://doi.org/10.1038/s41598-025-96710-3openalex-snapshot
Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases
inferred← citeshttps://doi.org/10.1038/s41598-026-37852-wopenalex-snapshot
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study
inferred← citeshttps://doi.org/10.1039/d4fo05280copenalex-snapshot
Lactobacillus acidophilus KLDS1.0901 ameliorates non-alcoholic fatty liver disease by modulating the tryptophan metabolite indole-3-aldehyde and acting on its receptor AhR
inferred← citeshttps://doi.org/10.1053/j.ajkd.2023.08.016openalex-snapshot
Association of Stroke With Metabolic Dysfunction–Associated Fatty Liver Disease With and Without CKD
inferred← citeshttps://doi.org/10.1053/j.gastro.2024.03.017openalex-snapshot
Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
inferred← citeshttps://doi.org/10.1053/j.gastro.2026.06.003openalex-snapshot
Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening
inferred← citeshttps://doi.org/10.1080/00365521.2023.2179864openalex-snapshot
Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease
inferred← citeshttps://doi.org/10.1080/00365521.2024.2395851openalex-snapshot
Anti-inflammatory diet reduces risk of metabolic dysfunction-associated fatty liver disease among US adults: a nationwide survey
inferred← citeshttps://doi.org/10.1080/07853890.2023.2211349openalex-snapshot
Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey
inferred← citeshttps://doi.org/10.1080/07853890.2023.2216943openalex-snapshot
Close association of PFASs exposure with hepatic fibrosis than steatosis: evidences from NHANES 2017–2018
inferred← citeshttps://doi.org/10.1080/09540105.2025.2496499openalex-snapshot
Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
inferred← citeshttps://doi.org/10.1080/14656566.2024.2426680openalex-snapshot
Metabolic-associated steatotic liver disease and hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000016openalex-snapshot
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/hep.0000000000000396openalex-snapshot
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
inferred← citeshttps://doi.org/10.1097/hep.0000000000000397openalex-snapshot
Reply: NAFLD/MAFLD: One size does not fit all, certainly not for children!
inferred← citeshttps://doi.org/10.1097/hep.0000000000000587openalex-snapshot
Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with “Ludwig disease”
inferred← citeshttps://doi.org/10.1097/hep.0000000000000706openalex-snapshot
From NAFLD to MASLD: Promise and pitfalls of a new definition†
inferred← citeshttps://doi.org/10.1097/hep.0000000000000837openalex-snapshot
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
inferred← citeshttps://doi.org/10.1097/id9.0000000000000085openalex-snapshot
Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
inferred← citeshttps://doi.org/10.1097/jcma.0000000000001230openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease and its associated health risks
inferred← citeshttps://doi.org/10.1097/js9.0000000000002680openalex-snapshot
Integrated network toxicology and population-based analysis uncovers organophosphate flame retardant exposure as a risk factor for hepatic steatosis and fibrosis: mechanistic and clinical insights
inferred← citeshttps://doi.org/10.1097/md.0000000000041455openalex-snapshot
Metabolic dysfunction–associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/md.0000000000048008openalex-snapshot
Association between blood selenium level and nonalcoholic fatty liver disease among naturally menopausal women: A cross-sectional study
inferred← citeshttps://doi.org/10.1097/med.0000000000000803openalex-snapshot
Cardiovascular disease in metabolic-associated fatty liver disease
inferred← citeshttps://doi.org/10.1097/meg.0000000000002497openalex-snapshot
Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
inferred← citeshttps://doi.org/10.1097/meg.0000000000002963openalex-snapshot
Association of free triiodothyronine and total triiodothyronine with nonalcoholic fatty liver disease: from National Health and Nutrition Examination Survey and Mendelian randomization study
inferred← citeshttps://doi.org/10.1097/meg.0000000000002977openalex-snapshot
Heterogeneity of cardiometabolic and hepatic fibrosis risks in nonalcoholic fatty liver disease among lean, overweight, and obese populations: a multicenter cross-sectional study
inferred← citeshttps://doi.org/10.1097/meg.0000000000003040openalex-snapshot
Differential effects of sleep duration on cardiovascular risk in metabolic-associated fatty liver disease vs. without metabolic-associated fatty liver disease: evidence from National Health and Nutrition Examination Survey and Mendelian randomization
inferred← citeshttps://doi.org/10.1097/meg.0000000000003174openalex-snapshot
Diagnostic and prognostic performance of the fibrotic nonalcoholic steatohepatitis index in patients with metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1101/2023.09.26.23296130openalex-snapshot
Comparison of NAFLD, MAFLD, MASLD and pure-MASLD characteristics and mortality outcomes in United States adults
inferred← citeshttps://doi.org/10.1101/2024.09.07.24313248openalex-snapshot
A Comprehensive Study on the Impact of Hypertension on Bone Metabolism Abnormalities Based on NHANES Data and Machine Learning Algorithms
inferred← citeshttps://doi.org/10.1111/apt.17723openalex-snapshot
Letter: Detecting unreported alcohol consumption in patients with NAFLD —Standardisation is urgent
inferred← citeshttps://doi.org/10.1111/apt.17833openalex-snapshot
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
inferred← citeshttps://doi.org/10.1111/apt.18039openalex-snapshot
Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
inferred← citeshttps://doi.org/10.1111/dom.16109openalex-snapshot
The fibrosis investigating navigator in diabetes ( FIND ): A tool to predict liver fibrosis risk in subjects with diabetes
inferred← citeshttps://doi.org/10.1111/hepr.13888openalex-snapshot
Fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease: A prospective study
inferred← citeshttps://doi.org/10.1111/hepr.13898openalex-snapshot
Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease
inferred← citeshttps://doi.org/10.1111/hepr.14004openalex-snapshot
New concept in fatty liver diseases
inferred← citeshttps://doi.org/10.1111/hepr.14011openalex-snapshot
Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1111/jgh.16592openalex-snapshot
Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease
inferred← citeshttps://doi.org/10.1111/liv.15555openalex-snapshot
The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis
inferred← citeshttps://doi.org/10.1111/liv.15856openalex-snapshot
Comparison of NAFLD , MAFLD and MASLD characteristics and mortality outcomes in United States adults
inferred← citeshttps://doi.org/10.1111/liv.16075openalex-snapshot
Clinical outcomes of MAFLD versus NAFLD : A meta‐analysis of observational studies
inferred← citeshttps://doi.org/10.1111/liv.16246openalex-snapshot
miR ‐18a‐5p/ PXR / SREBP2 Was Involved in MAFLD Associated With Methyl Tert‐Butyl Ether Among Petrol Station Workers
inferred← citeshttps://doi.org/10.1136/gutjnl-2023-331003openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
inferred← citeshttps://doi.org/10.1139/apnm-2026-0201openalex-snapshot
Association of serum carotenoids, steatotic liver disease, and metabolic dysfunctions with all-cause and cardiovascular disease mortality
inferred← citeshttps://doi.org/10.1161/jaha.125.044744openalex-snapshot
Associations Between Metabolic Score for Visceral Fat and Venous Thromboembolism Among 118 619 Participants With Metabolic Syndrome: Insights From Epidemiology to Genetic Susceptibility
inferred← citeshttps://doi.org/10.1186/s12876-024-03192-0openalex-snapshot
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
inferred← citeshttps://doi.org/10.1186/s12876-025-03752-yopenalex-snapshot
Biological age prediction and NAFLD risk assessment: a machine learning model based on a multicenter population in Nanchang, Jiangxi, China
inferred← citeshttps://doi.org/10.1186/s12876-025-03912-0openalex-snapshot
Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
inferred← citeshttps://doi.org/10.1186/s12889-024-20919-6openalex-snapshot
Life’s essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1186/s12902-026-02424-6openalex-snapshot
Fasting insulin to HDL-C ratio is correlated with MASLD severity in Chinese overweight/obesity: a cross-sectional analysis
inferred← citeshttps://doi.org/10.1186/s12944-025-02736-xopenalex-snapshot
The nomenclature of fatty liver disease and its impact on obesity traits, insulin resistance, and hepatic fibrosis
inferred← citeshttps://doi.org/10.1186/s12986-025-00898-0openalex-snapshot
Remnant cholesterol, a potential risk factor of metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1186/s40001-025-02936-2openalex-snapshot
The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study
inferred← citeshttps://doi.org/10.1186/s40842-026-00282-8openalex-snapshot
Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders
inferred← citeshttps://doi.org/10.1371/journal.pone.0299836openalex-snapshot
The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.14218/jcth.2022.00154openalex-snapshot
Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations
inferred← citeshttps://doi.org/10.14218/jcth.2024.00311openalex-snapshot
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
inferred← citeshttps://doi.org/10.14309/ajg.0000000000002778openalex-snapshot
Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes
inferred← citeshttps://doi.org/10.14309/ajg.0000000000002920openalex-snapshot
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
inferred← citeshttps://doi.org/10.14366/usg.24219openalex-snapshot
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
inferred← citeshttps://doi.org/10.1590/1414-431x2025e14538openalex-snapshot
The utility of an artificial intelligence model based on decision tree and evolution algorithm to evaluate steatotic liver disease in a primary care setting
inferred← citeshttps://doi.org/10.21037/hbsn-23-615openalex-snapshot
Impact of low alcohol consumption in the natural history of cirrhosis
inferred← citeshttps://doi.org/10.2147/dmso.s492153openalex-snapshot
Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China
inferred← citeshttps://doi.org/10.2147/dmso.s556539openalex-snapshot
Association of Fasting C-Peptide to High Density Lipoprotein Cholesterol Ratio with Non-Alcoholic Fatty Liver Disease in Chinese Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.21608/ejhm.2024.353351openalex-snapshot
Diabetic and Non-Diabetic Non-Alcoholic Fatty Liver Disease Patients: Assessment Using Non-Invasive Diagnostic Tools
inferred← citeshttps://doi.org/10.21614/sgo-642openalex-snapshot
Association between the Thyroid Hormone Levels and Metabolic Associated Fatty Liver Disease in Type 2 Diabetes Mellitus Egyptian Patients
inferred← citeshttps://doi.org/10.2957/kanzo.64.33openalex-snapshot
New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.31083/j.rcm2406157openalex-snapshot
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
inferred← citeshttps://doi.org/10.3350/cmh.2022.0367openalex-snapshot
MAFLD: How is it different from NAFLD?
inferred← citeshttps://doi.org/10.3350/cmh.2023.0084openalex-snapshot
The growing burden of non-alcoholic fatty liver disease on mortality
inferred← citeshttps://doi.org/10.3350/cmh.2024.0431openalex-snapshot
Epidemiology of metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.3389/fcimb.2025.1565298openalex-snapshot
Overweight and Helicobacter pylori infection: a correlation in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.3389/fendo.2022.1019204openalex-snapshot
The role of oxidized lipid species in insulin resistance and NASH in children
inferred← citeshttps://doi.org/10.3389/fendo.2023.1078149openalex-snapshot
Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
inferred← citeshttps://doi.org/10.3389/fendo.2023.1101892openalex-snapshot
Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III
inferred← citeshttps://doi.org/10.3389/fendo.2023.1308860openalex-snapshot
Editorial: Interaction of endocrine disorders and metabolic associated fatty liver disease: the genetic and epigenetic basis
inferred← citeshttps://doi.org/10.3389/fendo.2025.1480528openalex-snapshot
The association between phenotypes of polycystic ovary syndrome and metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.3389/fimmu.2022.959691openalex-snapshot
Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: A systematic review and meta-analysis of real-world evidences
inferred← citeshttps://doi.org/10.3389/fmed.2025.1569992openalex-snapshot
Association between perceived stress and MAFLD partially mediated by smoking and drinking
inferred← citeshttps://doi.org/10.3389/fnut.2022.1043901openalex-snapshot
Healthy Eating Index-2015 in relation to risk of metabolic dysfunction-associated fatty liver disease among US population: National Health and Nutrition Examination Survey 2017–2018
inferred← citeshttps://doi.org/10.3389/fnut.2026.1852189openalex-snapshot
Bletilla striata oligosaccharides alleviate high-fat diet-induced metabolic associated fatty liver in mice through modulation of gut microbiota and host metabolism
inferred← citeshttps://doi.org/10.3389/fonc.2022.983554openalex-snapshot
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
inferred← citeshttps://doi.org/10.3389/fped.2025.1522219openalex-snapshot
Association of blood manganese and selenium levels with hepatic steatosis among adolescents: a nationwide cross-sectional analysis
inferred← citeshttps://doi.org/10.3389/fpubh.2026.1793888openalex-snapshot
Association between occupational noise exposure and metabolic dysfunction-associated fatty liver disease: the mediating role of body mass index in automotive manufacturing workers
inferred← citeshttps://doi.org/10.3390/biomedicines11041097openalex-snapshot
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
inferred← citeshttps://doi.org/10.3390/cancers14236012openalex-snapshot
Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
inferred← citeshttps://doi.org/10.3390/diagnostics12112822openalex-snapshot
Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area
inferred← citeshttps://doi.org/10.3390/diagnostics13040788openalex-snapshot
How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography—A Review of the Literature and Proposed Multistep Approach
inferred← citeshttps://doi.org/10.3390/ijms24076123openalex-snapshot
Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/ijms241310718openalex-snapshot
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
inferred← citeshttps://doi.org/10.3390/life15050696openalex-snapshot
Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.3390/nu14214505openalex-snapshot
Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017–2018
inferred← citeshttps://doi.org/10.3390/nu15224757openalex-snapshot
The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression
inferred← citeshttps://doi.org/10.3390/nu16081169openalex-snapshot
Supplementation of Silymarin Alone or in Combination with Salvianolic Acids B and Puerarin Regulates Gut Microbiota and Its Metabolism to Improve High-Fat Diet-Induced NAFLD in Mice
inferred← citeshttps://doi.org/10.3390/ph18091279openalex-snapshot
Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.37349/emed.2025.1001281openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
inferred← citeshttps://doi.org/10.37349/emed.2025.1001365openalex-snapshot
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
inferred← citeshttps://doi.org/10.3748/wjg.v29.i3.549openalex-snapshot
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact
inferred← citeshttps://doi.org/10.4093/dmj.2024.0042openalex-snapshot
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
inferred← citeshttps://doi.org/10.4178/epih.e2024024openalex-snapshot
Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort
inferred← citeshttps://doi.org/10.4254/wjh.v15.i12.1253openalex-snapshot
From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
inferred← citeshttps://doi.org/10.4254/wjh.v15.i4.477openalex-snapshot
Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes
inferred← citeshttps://doi.org/10.4291/wjgp.v15.i1.92864openalex-snapshot
Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
inferred← citeshttps://doi.org/10.5005/jp-journals-10018-1424openalex-snapshot
Nonalcoholic Fatty Liver Disease vs Metabolic-associated Fatty Liver Disease vs Metabolic Dysfunction-associated Steatotic Liver Disease: What\'s in the Name?
inferred← citeshttps://doi.org/10.5009/gnl230222openalex-snapshot
Unraveling Metabolic Dysfunction-Associated Fatty Liver Disease: Refining Sub-Phenotypes for Resolving Its Heterogeneity
inferred← citeshttps://doi.org/10.5009/gnl250275openalex-snapshot
Mortality and Cardiovascular Outcomes in Patients with MAFLD Compared with Patients with MASLD: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.5152/tjg.2023.22679openalex-snapshot
Liver Transplantation for Hepatocellular Carcinoma in Patients with Inherited Metabolic Liver Diseases: A Single-Center Analysis
inferred← citeshttps://doi.org/10.55729/2000-9666.1426openalex-snapshot
MAFLD: Exploring the Systemic Effects Beyond Liver.
inferred← citeshttps://doi.org/10.5772/intechopen.104299openalex-snapshot
Advances in Probiotics for Health and Nutrition
inferred← citeshttps://doi.org/10.5772/intechopen.110134openalex-snapshot
Nonalcoholic Fatty Liver Disease, Procalcitonin, and Gut Microbiota: Players in the Same Team
inferred← citeshttps://doi.org/10.6084/m9.figshare.25422329openalex-snapshot
Additional file 1 of The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.